Mr Blumenthal has over 10 years experience in Investment Banking and Corporate Finance. He has exposure to Australian and International markets, having provided capital raising and financing solutions to an number of unlisted and listed companies. Adam has played a lead role in advising and supporting multiple organisations across a broad spectrum of industries, using his experience and network of international contacts to provide corporate advisory and capital markets input. He has successfully brought to market several Medical Marijuana companies spanning Israel, Canada, Switzerland and Australia. He has also been actively involved in the Mining, Cyber Security, Health Care and IT sectors. Adam is a director of EverBlu Capital Pty Ltd, the Company's appointed corporate advisor and lead manager to the various capital raisings undertaken by the Company in CY2020. Outside of his formal business activities, Adam has lectured at a leading Sydney University covering corporate governance, corporate social responsibility and ASX listings - both at an undergraduate and postgraduate level. He is a member of the Israel Business Club Sydney (IBCS).

Dr Ellingford has vast experience in the international arena and has successfully developed close ties with both financial institutions as well as governments throughout the world. Dr Ellingford's professional life culminated in being President of an international publicly listed billion-dollar business with its headquarters in Geneva, Switzerland and New York, USA. Dr Ellingford used to lecture MBA students in Corporate Governance at a leading Sydney University and has a keen interest in ethics. Dr Ellingford is chairman of Risk Committee.

Mr Wachtel was Co-Founder and former Managing Director of MMJ-PhytoTech Ltd, Australia's first publicly traded Medical Cannabis Company. Co-founder of IMCPC - International Medical Cannabis Patient Coalition. He is an Israeli medical cannabis pioneer/activist, who formulated and assisted the Ministry of Health with the implementation of the National Medical Cannabis Program - one of only few national programs in the world. He is a frequent lecturer and adviser to governments, national committees, business and NGO's on medical cannabis program formulation, grow operations, international laws and UN drug convention compliance, as well as the founder (1999) and former Chairman of the Green Leaf Party, an Israeli political party for cannabis legalisation/medicalisation, human rights and ecology. Mr Wachtel is member of Risk Committee.

Mr Linton is a cannabis executive and has sector experience as a founder, CEO, Board member and advisor to a number of global cannabis and psychedelic focused companies. Mr Linton's experience include his role as founder, Chairman and ex-CEO of Canopy Group Corporation. Mr Linton was also responsible for securing market support for 16 funding rounds and progressing over 30 M&A opportunities. He led Canopy Growth through its start-up phase to becoming the first producing cannabis company to list on the New York Stock Exchange. Following his departure from Canopy Growth, he has led direct investments into the cannabis and psychedelic sector while undertaking management and strategic advisory roles. These include being Executive Chairman of Gage Cannabis Co. and a Director of psychedelic medicines company, Mind Medicines Inc.

Mr Lay is an experienced cannabis executive and previously served as Executive Vice President - Strategy, Origination & Operations at Creso Pharma (refer ASX announcement: 6 September 2021). Mr Lay began his career with Canadian full service financial investment bank, BMO Capital Markets through roles across Canada and London. Shortly after his time with BMO Capital Markets, Mr Lay joined Canopy Growth Corporation (TSE: WEED, NASDAQ: CGC) as an M&A Associate, before being promoted to Associate Director, M&A, in 2019. In this role, he assessed and effected multiple transactions locally and internationally, while concurrently progressing corporate strategy initiatives across the group. Over the last four years, Mr Lay has managed and supported cannabis M&A transactions, including managing the acquisition in the history of the cannabis sector.

Mrs MacKay has 22 years of experience in regulatory environments, including pharmaceuticals, medical devices, and government regulated industries. She has held leadership positions for many years in different areas with a focus on business improvements and product development from laboratory scale to commercial operations. Mrs MacKay is currently the Corporate Manager of Creso Pharma's wholly owned Canadian subsidiary, Mernova Medicinal Inc. (Mernova). She has been in the position for nearly three years and is responsible for multiple functions including HR, quality assurance, and regulatory affairs. Mrs MacKay is the Health Canada designated Responsible Person in Charge at Mernova. She has practical experience in managing a business through specified key performance indicators, managing budgets, conducting regular audits and performance management.

-

-

-

-

-